Stockreport

Savara Announces Manuscript on Long-Term Outcomes With Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) Published in ERJ Open Research

Savara, Inc.  (SVRA) 
Last savara, inc. earnings: 3/12 04:05 pm Check Earnings Report
US:NASDAQ Investor Relations: savarapharma.com/investors/events-presentations
PDF -- Real World, Retrospective Outcomes Data Suggest Molgramostim Addresses the Underlying Pathophysiology of aPAP Resulting in Improved Lung Function, Decreased Disease B [Read more]